Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Trial Profile

Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CHANCE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 08 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Feb 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 13 Aug 2012 Actual patient number changed from 66 to 70 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top